Affordable Access

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Authors
  • Maghzi, Amir Hadi
  • Houtchens, Maria K.
  • Preziosa, Paolo
  • Ionete, Carolina
  • Beretich, Biljana D.
  • Stankiewicz, James M.
  • Tauhid, Shahamat
  • Cabot, Ann
  • Berrios Morales, Idanis M.
  • Schwartz, Tamara H. W.
  • Sloane, Jacob A.
  • Freedman, Mark S.
  • Filippi, Massimo
  • Weiner, Howard L.
  • Bakshi, Rohit
Publication Date
Jun 03, 2020
Source
[email protected]
Keywords
License
Unknown
External links

Abstract

The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

Report this publication

Statistics

Seen <100 times